Skip to main content
SpringerLink
Log in

Issues to be considered for the introduction of new vaccines into national vaccination programmes

  • Chapter
The Grand Challenge for the Future

Part of the book series: Birkhäuser Advances in Infectious Diseases BAID ((BAID))

  • 739 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Henderson RH (1995) Vaccination: Successes and challenges. In FT Cutts, PG Smith (eds): Vaccination and world health. John Wiley & Sons, Chichester, 3–16

    Google Scholar 

  2. Atkinson S, Cheyne J (1994) Immunization in urban areas: Issues and strategies. Bull World Health Organ 72: 83–94

    Google Scholar 

  3. Wenger JD, DiFabio J, Landaverde JM, Levine OS, Gaafar T (1999) Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four “newly adopting” countries. Vaccine 18: 736–742

    Article  PubMed  CAS  Google Scholar 

  4. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, Weber M, Palmer A, Schneider G, Jobe K et al (1997) Randomised trial of Haemophilus influenzae type b-tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 349: 1191–1197

    Article  PubMed  CAS  Google Scholar 

  5. World health Organization (2004) Vaccine Introduction Guidelines (WHO/V&B/04/00) Geneva, WHO, 2004. Available at http://www.who.int/vaccines-documents/DocsPDF04/www000.pdf

    Google Scholar 

  6. World Health Organization. Document WHO/VSQ/GEN/96.02 available from the VAB documentation centre, WHO, 1211 Geneva, Switzerland

    Google Scholar 

  7. World Health Organization (2002) Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies (WHO/V&B/02.08) Geneva, WHO, 2002. Available at http://www.who.int/vaccines-documents/DocsPDF02/www675.pdf

    Google Scholar 

  8. Mulholland EK, Bjorvatn B (2003) Introduction of new vaccines in the health care system. In: BR Bloom, P-H Lambert (eds): The vaccine book. Academic Press, San Diego and London, 391–410

    Google Scholar 

  9. Di Fabio JL, de Quadros C (2001) Considerations for combination vaccine development and use in the developing world. Clin Infect Dis 33(Suppl 4): S340–S345

    PubMed  Google Scholar 

  10. Jaffar S, Leach A, Smith PG, Cutts F, Greenwood B (2003) Effects of misclassification of causes of death on the power of a trial to assess the efficacy of a pneumococcal conjugate vaccine in The Gambia. Int J Epid 32: 430–436

    Article  Google Scholar 

  11. Halsey NA (2003) Vaccine safety: real and perceived issues. In: BR Bloom, PH Lambert (eds): The vaccine book. Academic Press, San Diego and London, 371–389

    Google Scholar 

  12. Gangarosa EJ, Galazka AM, Wolfe CR, Phillips LM, Gangarosa RE, Miller E, Chen RT (1998) Impact of anti-vaccine movements on pertussis control: the untold story. Lancet 351: 356–361

    Article  PubMed  CAS  Google Scholar 

  13. Institute of Medicine (1994) Adverse events associated with childhood vaccines: Evidence bearing on causality. National Academy Press, Washington, DC

    Google Scholar 

  14. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S (2001) Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 344: 319–326

    Article  PubMed  CAS  Google Scholar 

  15. Ball LK, Ball R, Pratt RD (2001) An assessment of thimerosal use in childhood vaccines. Pediatrics 107: 1147–1154

    Article  PubMed  CAS  Google Scholar 

  16. Cutts FT, Olivé J-M (1999) Vaccination programs in developing countries. In: SA Plotkin, WA Orenstein (eds): Vaccines (3d ed). Saunders, Harcourt, Philadelphia, 1047–1073

    Google Scholar 

  17. Creese A, Sriyabbaya N, Casabal G, Wiseso G (1982) Cost-effectiveness appraisal of immunization programmes. Bull World Health Organ 60: 621–632

    PubMed  CAS  Google Scholar 

  18. Hinman AR (1999) Economic aspects of vaccines and immunizations. CR Acad Sci III 322: 989–994

    CAS  Google Scholar 

  19. Batson A (1998) Sustainable introduction of affordable vaccines: the targeting strategy. Vaccine 16(Suppl): S93–S98

    PubMed  Google Scholar 

  20. Global Alliance for Vaccines and Immunization. Immunization financing options — A resource for policy makers. Available at http://www.gaviftf.org/docs_activities/briefcase/briefcase_web.pdf

    Google Scholar 

  21. Mahoney RT, Ramachandran S, Xu Z (2000) The introduction of new vaccines into developing countries II. Vaccine financing. Vaccine 18: 2625–2635

    Article  PubMed  CAS  Google Scholar 

  22. Clemens J, Brennen R, Rao M, Tafari N, Lowe C (1996) Evaluating new vaccines for developing countries. Efficacy or effectiveness? JAMA 275: 390–397

    Article  PubMed  CAS  Google Scholar 

  23. Trotter CL, Edmunds WJ (2002) Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ 324: 809–812

    Article  PubMed  Google Scholar 

  24. Edmunds WJ, Dejene A, Mekonnen Y, Haile M, Alemnu W, Nokes DJ (2000) The cost of integrating hepatitis B virus vaccine into national immunization programmes: a case study from Addis Ababa. Health Policy Planning 15: 408–416

    CAS  Google Scholar 

  25. World Bank (1993) World Development Report 1993. Investing in Health. Oxford University Press, Oxford, 1–329

    Google Scholar 

  26. Streefland PH (2003) Introduction of a HIV vaccine in developing countries. Social and cultural dimensions. Vaccine 21: 1304–1309

    Article  PubMed  CAS  Google Scholar 

  27. Suresh K, Saxema D (2000) Trends and determinants of immunization coverage in India. J Ind Med Assoc 98: 10–14

    CAS  Google Scholar 

  28. Hausdorff WP (1996) Prospects of the use of new vaccines in developing countries: cost is not the only impediment. Vaccine 14: 1179–1186

    Article  PubMed  CAS  Google Scholar 

  29. Balinska MA (2003) Vaccination in tomorrow’s society. Lancet Infect Dis 3: 443–447

    PubMed  Google Scholar 

  30. World Health Organization (2004) Hepatitis B vaccine. WHO position paper. Weekly Epidemiol Record 79: 255–263

    Google Scholar 

  31. World Health Organization (2003) Yellow fever vaccine. WHO position paper. Weekly Epidemiol Record 78: 349–359

    Google Scholar 

  32. World Health Organization (2004) Measles vaccine. WHO position paper. Weekly Epidemiol Record 79: 130–142

    Google Scholar 

  33. World Health Organization (2000) Rubella vaccine. WHO position paper. Weekly Epidemiol Record 75: 161–169

    Google Scholar 

  34. World Health Organization (2003) Pneumococcal vaccines. WHO position paper. Weekly Epidemiol Record 78: 110–119

    Google Scholar 

  35. World Health Organization (1999) Rotavirus vaccines. WHO position paper. Weekly Epidemiol Record 74: 33–40

    Google Scholar 

  36. World Health Organization (2003) Rotavirus vaccines, an update. Weekly Epidemiol Record 78: 2–3

    Google Scholar 

  37. World Health Organization (1998) Haemophilus influenzae type b conjugate vaccine. WHO Position paper. Weekly Epidemiol Record 73, 64–71

    Google Scholar 

  38. Anonymous (1999) Introduction of Hib vaccines in the Americas: lessons learned. EPI Newsletter 21: 4–5

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for International Health, University of Bergen, Armauer Hansen Building, Haukeland University Hospital, N-5021, Bergen, Norway

    Bjarne Bjorvatn

Authors
  1. Bjarne Bjorvatn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max Planck Institute for Infection Biology, Schumannstrasse 21-22, D-10117, Berlin, Germany

    Stefan H.E. Kaufmann

  2. CMU — Centre of Vaccinology, 1 rue Michel Servet, CH-1211, Geneva 4, Switzerland

    Paul-Henri Lambert

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

Bjorvatn, B. (2005). Issues to be considered for the introduction of new vaccines into national vaccination programmes. In: Kaufmann, S.H., Lambert, PH. (eds) The Grand Challenge for the Future. Birkhäuser Advances in Infectious Diseases BAID. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7381-4_13

Download citation

  • DOI: https://doi.org/10.1007/3-7643-7381-4_13

  • Publisher Name: Birkhäuser Basel

  • Print ISBN: 978-3-7643-7175-3

  • Online ISBN: 978-3-7643-7381-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation